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Abstract 
Background: Supervised cardio-pulmonary rehabilitation may be safe and beneficial for people with 
pulmonary hypertension (PH) in groups 1 (pulmonary arterial hypertension) and 4 (chronic thromboembolic 
disease), particularly as a hospital in-patient. It has not been tested in the most common PH groups; 2 (left 
heart disease), 3 (lung disease), or 5 (other disorders). Further it has not been evaluated in the UK National 
Health Service (NHS) out-patient setting, or with long-term follow-up. The aim of this randomised controlled 
trial (RCT) is to test the clinical and cost-effectiveness of a supervised exercise rehabilitation intervention with 
psychosocial support compared to best practice usual care for people with PH in the community/outpatient 
setting. 
(Continued on next page) 
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(Continued from previous page) 
Methods: This multi-centre, pragmatic, two-arm RCT with embedded process evaluation aims to recruit 352 
clinically stable adults with PH (groups 1–5) and WHO functional class II-IV. Participants will be randomised to 
either the Supervised Pulmonary Hypertension Exercise Rehabilitation (SPHERe) intervention or control. The 
SPHERe intervention consists of 1) individual assessment and familiarisation sessions; 2) 8-week, twice-weekly, 
supervised out-patient exercise training; 3) psychosocial/motivational support and education; 4) guided home 
exercise plan. The control intervention consists of best practice usual care with a single one-to-one 
practitioner appointment, and general advice on physical activity. Outcomes will be measured at baseline, 4 
months (post-intervention) and 12 months by researchers blinded to treatment allocation. The primary 
outcome is the incremental shuttle walk test at 4 months. Secondary outcomes include health-related quality 
of life (HRQoL), time to clinical worsening and health and social care use. A purposive sample of participants 
(n = 20  intervention  and  n = 20 control) and practitioners (n = 20) will be interviewed to explore experiences 
of the trial, outcomes and interventions. 
Discussion: The SPHERe study is the first multi-centre clinical RCT to assess the clinical and cost effectiveness 
of a supervised exercise rehabilitation intervention compared to usual care, delivered in the UK NHS, for 
people in all PH groups. Results will inform clinicians and commissioners as to whether or not supervised 
exercise rehabilitation is effective and should be routinely provided for people with PH. 
Trial registration: ISRCTN no. 10608766, prospectively registered on 18th March 2019. 
Keywords: Pulmonary hypertension, Cardiac rehabilitation, Pulmonary rehabilitation, Randomised controlled 
trial, Complex intervention 
Background 
Pulmonary hypertension (PH) is a debilitating condition 
causing dyspnoea, fatigue, palpitations, dizziness, and 
chest pain [1]. Many affected people are anxious about, 
and avoid, physical activity. Depression is common, and 
quality of life (QoL) can be poor [2]. There are five diag-
nostic groups: Group 1 pulmonary arterial hypertension 
(PAH); Group 2 PH due to left heart disease; Group 3 
PH due to lung diseases or hypoxia; Group 4 chronic 
thromboembolic PH (CTEPH); Group 5 PH due to other 
disorders [3]. Drug treatment and pulmonary endarter-
ectomy may help people with PAH [4] and CTEPH [5], 
respectively, but benefit is often limited. For people with 
PH secondary to cardiac or pulmonary disease (groups 2 
& 3), there are no treatments of proven benefit [6, 7]. 
Exercise rehabilitation appears to be safe and may help 
people with PAH and CTEPH, particularly when under-
taken as a hospital in-patient [8]. Recent recommenda-
tions support a conservative approach, under the careful 
supervision of appropriately skilled practitioners [3, 9]. 
However, exercise rehabilitation has not been tested in 
those with the most common forms of PH (groups 2 & 
3), or in an out-patient setting in the UK [6, 7, 10]. For 
people living with chronic heart failure (CHF) or chronic 
obstructive pulmonary disease (COPD), without co-
existing PH, exercise rehabilitation is recommended by 
NICE [11], and the British Thoracic Society [12], sup-
ported by a considerable evidence base [13]. Exercise re-
habilitation can improve fitness in these populations, 
and increase ability to ‘self-manage’, often reducing 
health and care utilisation [13, 14]. Thus, it is plausible, 
that exercise may also help people in other PH groups 
with underlying cardiac and pulmonary disease [7, 15]. 
A 2017 Cochrane review of exercise rehabilitation for 
PH identified six RCTs (N = 206 mainly people with 
PAH or CTEPH) with short follow-up (3–15 weeks) 
[16]. Low quality evidence showed that exercise rehabili-
tation programmes increased six-minute walk test 
(6MWT) distance by 60 m, compared to usual care (95% 
CI 30 m to 90 m), without any serious adverse events 
[17]. The SF-36 physical component score improved by 
4.63 points (95% CI 0.80 to 8.47), but this was not con-
sidered clinically important. Few studies have tested ex-
ercise rehabilitation for PH secondary to cardiac and 
pulmonary disease (groups 2 & 3) [18, 19]. 
Rationale for a trial 
In-patient exercise rehabilitation may have short-term bene-
fit on exercise capacity in selected people with PAH or 
CTEPH. However, it is not known if these benefits extend to 
people in PH groups 2, 3, & 5, if exercise rehabilitation deliv-
ered in an NHS out-patient setting is effective, or if there are 
any long-term health benefits or harms. To date there have 
been no high-quality, multi-centre RCTs to test the clinical 
and cost effectiveness of supervised exercise rehabilitation 
with psychosocial support compared to best-practice usual 
care delivered in the UK NHS out-patient setting. 
Methods/design 
Aims and objectives 
The aim of the trial is to assess the clinical and cost-
effectiveness of the Supervised Pulmonary Hypertension 
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Exercise Rehabilitation (SPHERe) intervention compared 
to best-practice usual care for people with PH. 
Objectives 
The objective is to run a definitive multi-centre prag-
matic RCT testing the clinical and cost-effectiveness of 
the SPHERe intervention compared to best-practice 
usual care, including: 
1. A pre-pilot to test feasibility, refine intervention de-
livery and manualised practitioner training, and pre-
pare trial set-up at selected centres; 
2. An internal pilot, with formative process evaluation, 
at a sample of out-patient centres to test recruit-
ment and trial procedures; 
3. A main trial with embedded process evaluation. 
Trial design and setting 
This protocol follows guidance from the Standard Proto-
col Items: Recommendations for Interventional Trials 
(SPIRIT) [20]. A SPIRIT schedule of enrolment, inter-
ventions and assessment is provided in Fig. 1 and a 
SPIRIT checklist is provided in Additional File 1. 
SPHERe is a multicentre, pragmatic, parallel, two-arm 
RCT with internal pilot study and embedded economic 
evaluation and qualitative study (Fig. 2). The trial will re-
cruit from up to 20 NHS cardio-pulmonary rehabilita-
tion centres in England. Participants will be randomised 
in a 1.15:1 ratio between intervention and control arms. 
Trial methods and design are summarised in the World 
Health Organization (WHO) Trial Registration Data Set 
(Table 1). 
Table 1 World Health Organization (WHO) Trial 
Registration Data Set. 
Pre-pilot feasibility study 
A pre-pilot feasibility phase was undertaken (August – 
December 2019) to complete the development of inter-
vention and trial materials, refine recruitment processes, 
pilot practitioner training, and confirm feasibility of 
intervention delivery. Over this period, the constituent 
parts of the SPHERe intervention were tested with four 
participants recruited from one centre. Full details of the 
development of the SPHERe intervention will be re-
ported elsewhere. 
Internal pilot 
From four NHS Trusts, 60 participants (25–30 per 
arm) will be enrolled to test the logistical processes 
of the study [21]. The pilot phase will last 6 months 
and will run seamlessly into the main trial if recruit-
ment targets are achieved. As a benchmark, if recruit-
ment is less than 50% of the target, the trial will not 
continue. If 50 to 75% of the target is achieved, 
recruitment will be reviewed at each Trust, a report 
will be submitted to regulatory authorities, and the 
trial will continue with modified recruitment strat-
egies and close monitoring. 
Eligibility criteria 
Adults with PH are eligible to participate if they meet 
the trial inclusion criteria (Table 2): 
Participant identification, recruitment and informed 
consent 
Participants will be identified by the clinical care 
team, via a number of co-ordinated screening strat-
egies. Primarily, local secondary care disease registers 
and hospital discharge data (International Statistical 
Classification of Diseases and Related Health Prob-
lems, 10th Revision [ICD-10]) will be screened. In 
addition, people with less common PH aetiology (who 
may not be captured through other routes), and those 
with a high probability of PH based on echocardio-
graphic findings [3], will be identified in specialist 
nurse/medical clinics. 
Further to the participant information leaflet being 
sent in the post, and the subsequent receipt of an ex-
pression of interest form from the potential participant, 
a member of the clinical team at the relevant site will 
contact the participant and invite them to attend a base-
line assessment appointment. At this face to face ap-
pointment, prior to randomisation, eligibility will be 
confirmed, and consent taken by an appropriately 
trained member of the clinical or research team. Specif-
ically, consent will be sought for the following; 1) trial 
participation, 2) review of medical notes by responsible 
individuals, 3) collection, storage and use of personal 
identifiable information by authorised individuals, 4) ac-
cess to long-term health and care information via NHS 
Digital and other NHS bodies, and 5) permission to con-
tact next of kin. 
Randomisation, allocation concealment and blinding 
Randomisation will be undertaken by Warwick Clin-
ical Trial Unit (WCTU) centralised service using a 
computer-generated sequence managed by a program-
mer independent from the study team. Minimisation 
variables include centre, PH group [1–5], and WHO 
functional class [two categories: 1) Class II; 2) Class 
III or IV]. To maintain allocation concealment, all 
baseline data will be collected prior to randomisation. 
The treating practitioner will only receive the ran-
domisation allocation electronically once all baseline 
measures are complete. To maintain blinding, all 
follow-up data will be collected by staff not directly 
involved in intervention delivery who are blind to 
treatment allocation. It is not possible to blind 
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STUDY PERIOD 
Enrolment Allocation Post-allocation 
TIMEPOINT -t1 0 
t1 
4 months 
t2 
12 months 
ENROLMENT: 
Eligibility screen 
Informed consent 
Randomisation 352 
Allocation 
INTERVENTIONS: 
SPHERe 189 
Usual care 163 
ASSESSMENTS: 
Incremental shuttle 
walk test 
Six-minute walk test 
CAMPHOR 
EQ-5D-5L 
HADS 
Generalised self-
efficacy scale 
Fatigue severity scale 
WHO functional class 
Time to clinical 
worsening 
Medication use 
Health/social care 
resource use 
All-cause mortality 
Adverse events 
Semi-structured
interviews 
Fig. 1 Schedule of enrolment, interventions, and assessments 
participants or practitioners to group allocation. Par-
ticipants will be asked not to tell the assessing practi-
tioner their group allocation when they attend their 
follow-up appointments. The quality of blinding will 
be tested by asking the outcome assessor which treat-
ment they thought each participant had received. 
Interventions 
The SPHERe intervention 
Format To ensure generalisability to the NHS, the 
underpinning framework of SPHERe is based on UK 
cardio-pulmonary rehabilitation guidelines and service 
delivery models [12, 24, 25], and enhanced with PH spe-
cific recommendations [3, 9, 12]. 
Cardio-pulmonary rehabilitation Participants rando-
mised to the SPHERe intervention will access existing 
cardio-pulmonary rehabilitation programmes. Service 
design in the UK is heterogeneous; some centres provide 
separate cardiac and pulmonary rehabilitation pro-
grammes, whereas others combine these programmes. 
This protocol will refer to these collectively as ‘cardio-
pulmonary rehabilitation’. 
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Fig. 2 Trial flow chart 
Programme design To maximise accessibility and re-
source, whilst ensuring that the benefits of group inter-
action are retained, SPHERe will be delivered as a ‘rolling’ 
programme. Participants randomised to the SPHERe 
intervention will be immediately referred to local services 
and invited to join existing cardio-pulmonary rehabilita-
tion programmes running at each centre, rather than 
waiting for the recruitment of sufficient numbers to form 
a discrete group of trial participants. The SPHERe inter-
vention has four components: 
Component 1. Individual assessment and exercise 
familiarisation 
Individual assessment 
A one-to-one appointment with a SPHERe ‘practitioner’ 
(specialist cardio-pulmonary clinical exercise physiolo-
gist or physiotherapist trained in intervention delivery). 
Participants will undergo an initial 1 hour ‘assessment’, 
as per standard practice. This will include assessment of 
medical history, medication, clinical parameters (i.e. 
height, weight, resting blood pressure, O2 saturation), 
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Table 1 World Health Organization Trial Registration Data Set 
Data category Information 
Primary registry and trial ISRCTN10608766 
identifying number 
Date of registration in 18th March 2019 
primary registry 
Secondary identifying REC reference: 19/WM/0155 
numbers NIHR HTA reference: 17/129/02 
Source(s) of monetary NIHR Health Technology Assessment grant 
or material support 
Primary sponsor UHCW NHS Trust 
University Hospital 
Clifford Bridge Rd., Coventry CV2 2DX 
Tel: 02476 966,195 
Email: R&DSponsorship@uhcw.nhs.uk 
Secondary sponsor(s) n/a 
Contact for public SPHERe Resource 
queries Warwick Clinical Trials Unit 
Tel: 02476150285 
Email: sphere@warwick.ac.uk 
Contact for scientific Dr Gordon McGregor 
queries Warwick Clinical Trials Unit 
Tel: 02476150285 
Email: gordon.mcgregor@warwick.ac.uk 
Public title Supervise exercise rehabilitation for people with pulmonary hypertension 
Scientific title Supervised Pulmonary Hypertension Exercise REhabilitation (SPHERe): a multi-centre randomised controlled trial 
Countries of recruitment England 
Health condition(s) or Pulmonary hypertension (PH) (groups 1–5) 
problem(s) studied 
Intervention(s) Intervention group: 1) Individual assessment and exercise familiarisation, 2) Supervised out-patient exercise programme, 3) 
Psychosocial and motivational support; and education, 4) Guided home exercise plan. 
Control intervention: Best practice usual care 
Key inclusion and Inclusion: Adults (18+) with confirmed PH (groups 1 to 5), clinically stable, WHO functional class II, III or IV, fluent in spoken 
exclusion criteria English, travelling distance of a SPHERe centre, ability to provide informed consent. 
Exclusion: Absolute contra-indications to exercise, PH-related complications, or comorbidities severe enough to prevent 
attendance at a SPHERe centre, or exercise, mental health issue preventing engagement with trial procedures, previous 
randomisation in SPHERe, pregnant at time of recruitment 
Study type Type: Pragmatic, interventional, multi-centre 
Allocation: randomised 
Assignment: parallel 
Masking: outcomes assessors, chief investigator, statistician 
Date of first enrolment 15th January 2020 
Target sample size 382 
Recruitment status Recruiting 
Primary outcome(s) Incremental shuttle walk test at four months 
Key secondary outcomes At 4 and 12 months: Six-minute walk test, Cambridge Pulmonary Hypertension Outcome Review, Hospital Anxiety and 
Depression Scale, Generalised self-efficacy scale, Fatigue Severity Scale, WHO functional class, Medication use, Time to 
clinical worsening, Hospital admissions, Adverse events, All-cause mortality, EQ-5D-5 L, Health and care resource use. 
At 12 months: Semi-structured interviews with participants and practitioners 
exercise/physical activity history, and discussion of par- Exercise prescription 
ticipant goals. Current exercise tolerance/capacity will The SPHERe practitioner will prescribe a tailored, indivi-
be assessed with the ISWT to inform exercise prescrip- dualised exercise programme within pre-specified pa-
tion starting level (this is a separate test to the ISWT rameters as per cardiac and pulmonary rehabilitation 
performed as an outcome measure). guidelines [12, 22, 24]. Clinical information, data from 
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Table 2 Inclusion and exclusion criteria 
Inclusion criteria Exclusion Criteria 
▪ Adults (18+) with confirmed PH (groups 1 to 5) as detailed in ESC/ERS 
guidelines [3]. 
▪ Clinically stable: Groups 1, 4, & 5 - stable on optimal PH specific drug 
therapy (for those in whom it is appropriate) for at least one month, or 
evidence that these drugs cannot be tolerated. Groups 2 & 3 - stable on 
drug therapy for underlying cardiac or pulmonary disease for at least one 
month. Clinical stability defined as: presenting with, reproducible, 
manageable symptoms, not requiring any treatment other than routine 
follow-up care, and no PH related hospital admission in the last four 
weeks. 
▪ World Health Organisation (WHO) functional class II, III or IV. 
▪ Fluent in spoken English to allow engagement with intervention and 
physical outcome measures. 
▪ Live within reasonable travelling distance (as defined by the 
participant) of a SPHERe exercise rehabilitation centre. 
▪ Ability to provide informed consent. 
▪ Absolute contra-indications to exercise as per international clinical 
guidelines [22, 23]. 
▪ PH-related complications, or comorbidities severe enough to prevent 
attendance at a SPHERe centre, or participation in exercise rehabilitation. 
▪ Any mental health issue that will prevent engagement with trial 
procedures. 
▪ Previous randomisation in the present trial 
▪ Pregnant at time of recruitment 
the exercise assessment, and patient centred goal setting 
will be used to devise a safe and effective exercise 
prescription. 
Familiarisation sessions 
Exercise guidance, specific to the underlying PH aeti-
ology, will be delivered on an individual basis during two 
one-to-one familiarisation exercise sessions in the first 
week of the programme. Familiarisation sessions will 
allow SPHERe practitioners to refine and optimise the 
exercise prescription. Practitioners will begin to intro-
duce the principles of psychosocial and motivational 
support during these sessions. 
Component 2. Supervised out-patient exercise 
programme 
The programme will run within existing cardio-
pulmonary rehabilitation programmes delivered by NHS 
clinical staff. Up to twice weekly, 1 h, supervised exercise 
sessions for the remaining seven to 10 weeks [12, 24] 
(maximum 14 sessions [16 sessions, including familiar-
isation sessions]), with a quantifiable and progressive 
dose of individualised, multi-modal, aerobic, muscular 
strength and endurance, and ‘functional fitness’ exercise. 
Adequate warm-up and cool-down will be incorporated. 
Intensity will be monitored and adjusted using heart 
rate, rating of perceived exertion, dyspnoea scale [26] 
and pulse oximetry (O2 saturation). 
The SPHERe exercise component is optimised to be 
appropriate for a broad spectrum of patients including 
deconditioned, low-mobility, exercise-naive participants. 
It is highly adaptable to allow personalisation to lower 
or higher ability participants, whilst ensuring safety and 
efficacy. The SPHERe exercise intervention combines 
conventional gym-based aerobic exercise with ‘functional 
fitness training’. This uses multi-plane motion to target 
not only cardiorespiratory fitness, but also essential pre-
requisites of active, independent living; e.g. agility, co-
ordination, proprioception, balance and functional 
strength [27]. In addition to treadmills, cycle and rowing 
ergometers, SPHERe will make use of low-cost, readily 
available, functional fitness equipment; e.g. steps, floor 
agility ladder, low rise balance beam, power bags, 
plyometric boxes, ball (throw/bounce) etc. Central to 
SPHERe is the expertise and experience of the specialist 
cardio-pulmonary exercise physiologists and physiother-
apist at all trial centres who will ensure holistic, safe, 
individualised and effective exercise training. This con-
forms to existing recommendations of specialist exercise 
supervision for this population [3, 9, 12]. 
Component 3. Psychosocial and motivational support; 
and education 
Once per week, before or after exercise, participants will 
receive a one-to-one 30 min psychosocial and motiv-
ational support session and a 30-min group education 
session (six sessions). The former will be delivered by a 
SPHERe practitioner, and the latter by clinical staff. 
Psychosocial and motivational support 
The aim is to improve short and long-term adherence to 
exercise, thus maximise benefit. As such, SPHERe will 
draw on social cognitive approaches to behaviour change 
[28], including scrutiny of multiple interactions between 
environment, personal factors and behaviours. Based on 
behaviour change techniques and the COM-B frame-
work, three basic aspects of peoples’ lives will be ad-
dressed: capability (psychological capability through 
education and planning, and physical capability through 
supervised practice), opportunity (providing support and 
guidance through the different components of the 
programme as well as exploring external opportunities 
(physical and social)), and motivation (through refection 
and discussion of health beliefs, illness representations, 
monitoring of progress and exploring emotional reason-
ing including possible feelings of anxiety, low mood and 
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fear) [29]. There will be a focus on increasing partici-
pants’ awareness of their priorities, through an investiga-
tion of the pros and cons of changing a specific 
behaviour (self-management e.g. fear avoidance of exer-
cise) and assisting them to develop a specific plan to 
change (planning, goal setting). Other components of 
the programme will include pacing of activities, man-
aging setbacks, stress and stress management as well as 
long term behaviour change. The SPHERe practitioners 
will be trained in motivational interviewing to assess pa-
tients’ current beliefs and encourage behaviour change. 
Comprehensive SPHERe manuals have been developed 
to guide participants and practitioners through each 
topic including case studies, working examples and 
visual aids. 
Education 
The underlying causes of PH are heterogeneous across 
the five PH groups [30]. It will, therefore, be essential for 
participants to access disease specific education. Equally, 
living with PH involves management of symptoms, expe-
riences and challenges that are common to all aetiologies 
of PH. SPHERe participants will access both generic and 
disease specific group education sessions (with non-trial 
cardio-pulmonary rehabilitation patients), provided by 
clinical staff at all SPHERe centres, as part of existing 
cardio-pulmonary rehabilitation services. All participants 
(regardless of PH group) will attend generic sessions, 
provided as standard clinical practice by existing clinical 
staff, on: 1) managing breathlessness; 2) breathing con-
trol and relaxation; 3) anxiety and depression; and 4) ac-
tivity pacing and energy conservation. 
Disease specific topics, which may include medication, 
sputum clearance, managing cardiac symptoms, risk fac-
tors, smoking cessation, oxygen therapy etc., provided 
routinely by clinical staff, will be accessed as relevant. 
For people with PH groups 2 & 3, this specialist advice/ 
education will be available as standard through the 
cardio-pulmonary rehabilitation programmes. Prior to 
enrolling in SPHERe, PH groups 1, 4, & 5 will have had 
discrete and extensive education with practitioners at 
local and national specialist clinics, as per their routine 
clinical treatment. 
Component 4. Guided home exercise plan 
To complement supervised exercise, all participants will 
be provided with a manualised home exercise plan. De-
tailed but simple information relating to replication of 
the supervised exercise they have undertaken, in the 
home-based setting, will be provided with written in-
structions and diagrams in the SPHERe intervention par-
ticipant manual. Each participant manual will include a 
diary to record time spent exercising. 
Control intervention: best practice usual care 
The control arm, will be an intervention that could be 
described as ‘best-practice usual care’, in the form of an 
individual practitioner appointment, with general advice 
on safe and effective physical activity for those living 
with PH. A single 30-min appointment will allow the 
practitioner to discuss individualised ways in which the 
participant can undertake physical activity at home. 
Control arm participants will not be given a structured 
exercise plan, rather comprehensive freely available Brit-
ish Lung Foundation ‘Keep Active’ booklet detailing 
ways in which low level physical activity can be safely 
and effectively incorporated into everyday life. No spe-
cific psychological techniques will be used to support 
the provision of this information. No further interven-
tion will be offered beyond this single advice session. 
Safety 
SPHERe will be delivered in cardio-pulmonary rehabili-
tation units with access to emergency equipment and 
qualified staff. Condition-specific monitoring of exercise 
responses, as per cardio-pulmonary rehabilitation guide-
lines, will reduce and manage risk [12, 22, 24]. Guided 
home exercise will be lower intensity and fully manua-
lised with instructions and photographic images. Inter-
vention practitioners will be specialist exercise 
physiologists or physiotherapists, experienced in assess-
ment, prescription and delivery of exercise in high risk 
clinical populations. Training in the standardised deliv-
ery of the SPHERe interventions and trial procedures 
will be provided for all practitioners, and bespoke man-
uals have been produced to guide delivery of all inter-
vention components. 
Primary outcome 
The primary outcome will be exercise capacity as deter-
mined by distance walked in the incremental shuttle walk 
test (ISWT) at 4 months (Fig. 1). The ISWT will be per-
formed as per European Respiratory Society (ERS)/Ameri-
can Thoracic Society (ATS) guidelines [17]. The externally 
paced ISWT is a simple assessment of maximal exercise 
capacity and, in PH, is sensitive to treatment effect, pre-
dicts mortality, and has no ceiling effect [31]. 
Secondary outcomes 
All outcomes will be assessed at baseline (pre-random-
isation), 4 months (post randomisation) and 12 months 
(Fig. 1). As a secondary measure of exercise capacity, to 
allow inclusion of data in future meta-analyses, the six-
minute walk test (6MWT) will be performed as per 
guidelines [17]. 
Disease specific health-related quality of life (HRQoL) 
will be measured with the Cambridge Pulmonary Hyper-
tension Outcome Review (CAMPHOR) [32]. This is 
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widely used as a clinical and research tool in PH, dis-
playing good construct validity and reproducibility. The 
full scale is 65 items consisting of a 25-item symptoms 
scale (scored 0–25), a 15-item functioning scale (scored 
0–30) and a 25-item QoL scale (scored 0–25). A total 
score and scores for each of the three sub-scales (symp-
toms, functioning, QoL) are produced; for all scales, a 
low score indicates a better status [32]. 
Health utility will be assessed with the EQ-5D-5 L 
[33], a validated, generic HRQoL measure consisting of 
five dimensions, each with five levels of response. Each 
combination of answers can be converted into a health 
utility score. It has good test-retest reliability, is simple 
to use, and gives a single preference-based index value 
for health status that can be used for cost-effectiveness 
analysis. Anxiety and depression will be measured with 
the Hospital Anxiety and Depression Scale (HADS) [34], 
a 14-item screening questionnaire from which an anxiety 
and depression subscale can be derived. Sub-score values 
> 5 points identify increased symptoms of anxiety and/or 
depression; a total score > 9 is considered indicative of 
psychological distress. Generalised self-efficacy scale will 
be assessed with a 10-item psychometric scale designed 
to assess optimistic self-beliefs to cope with a variety of 
difficult demands in life; these relate to key targets of the 
behavioural component of the SPHERe intervention. We 
will capture fatigue using the Fatigue Severity Scale 
(FSS) [35], a nine-item questionnaire validated for evalu-
ating disabling fatigue and previously used in PH [36]. 
Each item is rated on a seven-point scale, from strongly 
disagree to strongly agree. A total score is derived from 
all nine questions; a higher score indicates a greater im-
pact of fatigue on everyday activities. 
The World Health Organisation (WHO) functional 
class is a modified New York Heart Association func-
tional classification system adopted by WHO and used 
ubiquitously in PH. Participants will be graded on their 
ability to perform physical tasks, and classified as (I) no 
limitation, (II) mild limitation, (III) marked limitation, 
(IV) unable to perform any activity [37]. Medication 
class, drug, dose and frequency of all regular medication 
will be recorded as well as ‘time to clinical worsening’: 
defined as one of; PH related death; listing for/com-
pleted lung transplant; hospitalisation for PH; clinical 
worsening leading to initiation of new PH treatment; de-
creased WHO functional class and ≥ 15% decrease in 
6MWT distance [38]. Time to clinical worsening will be 
measured as the time that has elapsed since randomisa-
tion to the SPHERe trial. 
Health and social care resource use will be evaluated 
with participant self-report and NHS records. The pri-
mary health-economic analysis will concentrate on direct 
intervention and healthcare/personal social services 
costs, while wider impact (societal) costs will be included 
within the sensitivity analyses. Participants will complete 
resource use questionnaires in person or by post at four 
and 12 months, to collect resource use data associated 
with the interventions. Participants will be provided with 
a resource use diary as an aide memoire to help record 
resource use between four and 12 months. At the end of 
the follow-up period, a copy of medical records for the 
participant will be requested from their GP. This will 
provide information on GP consultations and include 
copies of any hospital discharge letters allowing accurate 
costing of in-patient care costs. Where appropriate, data 
will be triangulated from GP records, participant self-
report, and data held in participating hospitals, to 
achieve a robust estimate of health service activity. 
Finally, all-cause hospital admissions will be identified 
from GP records, adverse events recorded as per good 
clinical practice (GCP) guidelines, and all-cause mortal-
ity flagged via NHS digital to ensure notification of any 
deaths and cause of death both during the trial and for 
longer term follow-up. 
Follow-up 
Outcomes will be assessed at 4 months and 12 months 
post randomisation (Fig. 1). The primary outcome is an 
objective measure of exercise capacity for which partici-
pants will attend their treatment centre. Patient reported 
outcomes will also be collected at follow-up assessments. 
If any participants are unable to attend clinic, a postal 
questionnaire will be used to collect patient reported 
outcomes. In the case of non-response, two key second-
ary outcomes (CAMPHOR and EQ-5D-5 L) will be col-
lected by phone. For long-term follow-up, consent will 
be sought from participants to keep their personal data, 
and have access to their NHS data following the end of 
the current trial. This will allow longer term postal fol-
low up to assess QoL and to monitor deaths using NHS 
Digital data. 
Sample size 
The primary outcome will be distance walked measured 
using the ISWT at 4 months post-randomisation. As 
there are no directly applicable ISWT data with which 
to calculate a sample size, or previously defined worth-
while effect sizes for IWST in people with PH, 6MWT 
data have been used to estimate the sample size. The 
6MWT distance, unlike the alternative approach of 
using a standardised mean difference (SMD), has the ad-
vantage that it is meaningful to participants and 
grounded in clinical reality. 
The baseline pooled 6MWT distance in current stud-
ies of exercise rehabilitation for PH is 414 m (SD 91) 
[16]. Whilst a useful starting point, these data indicate a 
comparatively fit group of people with PH (younger, 
group 1 PH). Based on a sample from one cardio-
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pulmonary rehabilitation service at UHCW NHS Trust, 
typically, people with PH walk around 300 m in the 
6MWT. Conventionally, the minimally clinically import-
ant difference for PH studies is 30 m on 6MWT or an 
SMD of 0.33 [17]. Patient partners suggested that a lar-
ger difference was needed to make this treatment worth-
while. Therefore, sample size is predicated on showing a 
mean difference of 45 m in 6MWT distance. This 
equates to a standardised mean difference of 0.5; con-
ventionally a moderate effect size. 
To achieve 90% power at 5% significance level, to show 
a difference in 6MWT distance of 45 m, with a standard 
deviation of 90, data from 170 people are needed. Allow-
ance has been made for clustering effects by site in the 
intervention arm using Moerbeek’s method [39] and an 
unbalanced randomisation. Therefore, an unequal allo-
cation (1.15:1 for intervention vs control) was deter-
mined based on the following assumptions: a mean 
cluster size of 12 at follow-up, an intra-class correlation 
co-efficient (ICC) of 0.03 and same group variance. The 
ICC is an overall estimation of the site and practitioner 
effect, leading to an estimated design effect of 1.33, al-
though a negligible practitioner effect in this trial is an-
ticipated. Accordingly, the group sample sizes were 
calculated separately, given the power of 90% and a sig-
nificance level of 5%. An 80% retention rate is expected 
at 4 months. Therefore, 246 participants (132 in inter-
vention) will be recruited to allow for 20% loss to 
follow-up. 
The primary aim is to show an overall effect size for 
all PH groups without considering participant mix. 
Based on published data for prevalence of PAH and 
CTEPH, however, most participants will have PH groups 
2 or 3. Sufficient data will be collected to assess outcome 
in a pooled group of people with group 2 or 3 PH as a 
secondary analysis. Approximately 70% of the total sam-
ple size will be people with group 2 or 3 PH. To ensure 
power of 90% power, for this sub-group, the sample of 
246 will inflated to 352 participants (189 intervention, 
163 control). This will be the total sample for the trial 
which will ensure sufficient power for the main analysis 
as well as the sub-group analysis. There is some uncer-
tainty about the final sample size because of the need to 
include 246 people with group 2/3 PH in the overall 
population and an ambition to include a minimum of 20 
people each from PH groups 1, 4, & 5. 
Data analysis 
The main analyses will be for overall treatment effect re-
gardless of PH diagnostic group. Data will be sum-
marised and reported in accordance with CONSORT 
guidelines for RCTs, using intention-to-treat analyses 
[40]. Hierarchical linear regression models will be used 
to estimate the treatment effects (95% confidence 
intervals), adjusted for important patient-level covariates 
and centre effect. Estimation of, and adjustment for 
practitioner effects will be included. If there is negligible 
practitioner and centre effect, then the usual linear re-
gression will be used for the analysis. Categorical data 
will be assessed in a similar way, using logistic regression 
models. The main analyses will be intention to treat and 
will assess the impact of compliance on outcomes using 
a CACE (complier average causal effect) analysis. For the 
intervention group, full compliance will be considered as 
attending at least 75% of the supervised exercise ses-
sions. In addition, probabilities for achieving the desired 
effect size in each of the PH groups will be presented 
using the magnitude based inference approach [41].. 
In a planned secondary analysis the pooled effects for 
PH groups 2 & 3 will be presented. Pre-specified sub-
group analyses will examine the interaction of treatment 
assignment with the groupings of PH. Analysis will be 
conducted using formal tests of interaction. This trial is 
not powered to identify interactions, thus, whilst pre-
specified, these analyses should be considered as no 
more than exploratory. However, the effect size for 
pooled PH groups 2 & 3 will be presented as a separate 
analysis. Main outcomes will also be presented by diag-
nostic group (minimum 20 people contributing data) to 
inform decision makers and guidance developers inter-
ested in specific PH groups. To maximise data value, 
data from published trials (identified in an updated sys-
tematic review) assessing the same outcomes in RCTs of 
out-patient/community outreach interventions for spe-
cific PH group, will be included. The statistical methods 
will be further elaborated in a statistical analysis plan 
(SAP). 
Health economic evaluation and analysis 
A prospective economic evaluation, informed by the 
NICE Reference Case [42], will be finalised within a 
Health Economics Analysis plan (HEAP), prior to any 
analysis. The primary perspective will include NHS and 
Personal Social Services (PSS) costs. However, patient 
direct and indirect costs will also be included in a sec-
ondary broader societal perspective. Primary care and 
referral events will be captured both from health records 
and from participants, using a triangulation and adjudi-
cation approach to promote robust estimates of resource 
use. Participants will also report PSS and personal direct 
and indirect costs. Personal Social Services Research 
Unit (PSSRU) [43] and national hospital reference costs 
[44] will be used as principal unit cost sources. Patient 
level costs will be estimated by combining resource use 
data with unit cost. Intervention costing will reflect the 
structure within which care is being given and will, by 
necessity, balance precision with practicality. 
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EQ-5D-5 L responses will be used to generate quality-
adjusted life years (QALYs) using the UK value set rec-
ommended by NICE guidance at time of analysis [45]. 
These health state values will be used to estimate 
QALYs at the patient level, over 1 year, using the trapez-
oidal rule. The EQ-5D-5 L will be used as the overall 
HRQoL outcome due to specific concerns about the sen-
sitivity to change of other measures such as the SF-36, 
in this population. The EQ-5D-5 L is likely to be more 
responsive to change than the 3 L, and hence is pre-
ferred as a clinical outcome. Significant adverse events 
will be captured summatively in the HRQoL estimation. 
Decision modelling will be considered beyond the end of 
the trial if outcomes have not converged. 
It is anticipated that bivariate regression of costs and 
QALYs (with bootstrapping of models) will be used to 
generate incremental cost per QALY estimates and cred-
ible intervals, cost-effectiveness acceptability curves, and 
value-of-information analysis. With regard to normality, 
invoking the central limit theorem avoids the problems 
that non-Gaussian link functions generate for the ana-
lysis. However, if distributions are very unusual, cost and 
QALYs will be conflated in a net benefit analysis evalu-
ated at different thresholds of willingness to pay, redu-
cing the analysis to a univariate regression problem. 
Embedded process evaluation 
Semi-structured interviews will be conducted in person 
or on the phone/video call as appropriate. Intervention 
and control participants will be interviewed to investi-
gate their experiences, contextualise quantitative find-
ings, and explore factors that helped or hindered 
participation, thus informing interpretation and wider 
implementation. Interviews will take place after the 12-
month follow-up outcome data collection, so that the 
interview itself does not introduce bias to the analysis. A 
purposive sample of up to n = 20 intervention, n = 20  
control and n = 20 practitioner will be interviewed to 
ensure a diverse range of perspectives are included. The 
interviews will use a topic guide that will include partici-
pant response to the intervention (or control), what they 
found difficult, what worked well, specific obstacles and 
enablers, what components were used/dropped/never 
used, and views on the guided home exercise content. 
Interviews will last about 1 h, be digitally recorded, 
pseudo-anonymised, and transcribed verbatim. Data will 
be analysed using the Framework method [46]. Quanti-
tative and qualitative data will be integrated using a 
mixed methods matrix’ where quantitative responses can 
be compared to interview data [47] as described else-
where in the SPHERe intervention development 
publication. 
All psychosocial/motivational sessions and control (1:1 
session) sessions will be recorded. A purposively selected 
subset (10%) of recordings will be analysed, with a 
checklist to assess fidelity and help understand which 
areas generated discussion. Intervention fidelity will be 
assessed using the tenets highlighted by Mars et al. [47]. 
Data management and security 
All essential documentation and trial records will be 
stored in conformance with the applicable regulatory 
requirements, and access restricted to authorised 
personnel. Electronic data will be stored on password 
protected computers in a restricted access building. All 
data will be pseudonymised after the collection of the 
baseline demographic data. For quality assurance, the 
data and results will be routinely checked for complete-
ness and accuracy. Trial documentation and data will be 
archived for 10 years after completion of the trial. 
Trial management and monitoring 
The Trial Management Group, consisting of project staff 
and co-investigators involved in the day-to-day running 
of the trial, will meet monthly throughout the project. 
Any significant issues will be referred to the Trial Steer-
ing Committee (TSC) which will meet twice yearly and 
constitute a group of experienced personnel and trialists, 
‘lay’ representatives, and an independent Chairperson. A 
Data Monitoring Committee (DMC) consisting of inde-
pendent experts with relevant clinical research and stat-
istical experience, will meet twice yearly to ensure data 
integrity and participant safety. 
Adverse event management 
An Adverse Event (AE) will be defined as any untoward 
medical occurrence in a participant which does not ne-
cessarily have a causal relationship with the intervention. 
Any AEs related to SPHERe will be recorded and re-
ported to the relevant oversight committees. In this 
population, serious adverse events (SAE) are expected. 
Hospital admissions data will be collected through self-
report and GP records, and deaths via NHS Digital. 
SAEs that have no causal relationship with the interven-
tion will not be reported to oversight committees. Caus-
ality and expectedness will be confirmed by the CI with 
clinician support. SAEs deemed to be unexpected and 
possibly, probably or definitely related to the trial inter-
ventions will be notified to the Research Ethics Commit-
tee (REC) within 15 days. All AEs and SAEs will be 
recorded within 24 h of the investigator being made 
aware. 
Patient and public involvement 
The SPHERe intervention and trial were developed dur-
ing the grant funding application process and subse-
quently during the pre-pilot feasibility phase. Patient and 
public involvement was pivotal at every stage. A three-
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stage process was followed as per MRC guidance: 1) sys-
tematic literature review; 2) expert opinion, stakeholder 
engagement and consensus meetings; 3) intervention 
piloting, acceptability and refinement. Lay partners and 
co-applicants were fully integrated into every stage of 
trial development, taking an active role in refining inter-
vention components and reviewing the application. A lay 
co-applicant currently sits on the trial management 
group (TMG), initially meeting monthly and subse-
quently quarterly, and has a pivotal role in steering the 
conduct of the trial. She reviewed the ethics application 
to ensure that trial documentation e.g. participant infor-
mation leaflet, was user appropriate. Lay partners have 
been actively involved in trial publicity and media and 
will help with the dissemination of findings through ap-
propriate channels i.e. social media, lay conferences, 
public engagement events, service provider events, news-
letter articles. Lay partners also sit on the TSC as veri-
fied independent members. Lay co-apps and partners are 
supported by the chief investigator (CI), trial manage-
ment team, and through the peer support of lay partners 
on existing clinical trials. Comprehensive training and 
support was provided by WCTU. 
Discussion 
Pulmonary hypertension is life-limiting and can have a 
substantial impact on QoL [2]. Amongst numerous de-
bilitating symptoms, exertional breathlessness and fa-
tigue prevent completion of many activities of daily 
living [1]. For PH groups 2&3 in particular, there is a 
distinct lack of targeted therapies and treatment options. 
Exercise rehabilitation is routinely offered to people 
with many forms of heart and lung disease, but due to a 
lack of empirical data, is not currently provided for 
people with PH. The SPHERe study aims to address this 
evidence gap. It is the first multi-centre clinical trial to 
assess the clinical and cost effectiveness of a supervised 
out-patient exercise rehabilitation intervention com-
pared to best-practice usual care, delivered in the UK 
NHS, for people in all PH diagnostic groups. 
Results from the SPHERe study will inform many areas 
of clinical practice. Firstly, clinicians and rehabilitation 
practitioners will gain invaluable insight into the specific 
exercise rehabilitation requirements of people with PH. 
Secondly, they will have definitive answers as to the clin-
ical efficacy of NHS out-patient exercise rehabilitation 
programmes for this diverse population. Thirdly, com-
missioners will be able to appraise the cost-effectiveness 
of such programmes and inform commissioning strat-
egies accordingly. Finally, people with all forms of PH 
will be able to get an appreciation for the potential bene-
fit or harm of out-patient exercise rehabilitation and 
make informed decisions as to their future participation 
in physical activity and exercise programmes. Should the 
trial find that exercise rehabilitation is beneficial to 
health-related outcomes, the SPHERe supervised and 
home-based exercise rehabilitation resources will be 
made freely available to rehabilitation practitioners and 
people with PH. 
Trial status 
Recruitment to the internal pilot began in January 2020 
and was subsequently temporarily suspended in March 
2020 due to the Covid-19 pandemic. Trial activities are 
expected to recommence later in the year. 
Supplementary information 
Supplementary information accompanies this paper at https://doi.org/10. 
1186/s12890-020-01182-y. 
Additional file 1. SPIRIT 2013 Checklist: Recommended items to address 
in a clinical trial protocol and related documents*. 
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